Logo image of RYTM

RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

USA - NASDAQ:RYTM - US76243J1051 - Common Stock

101.63 USD
+0.99 (+0.98%)
Last: 9/30/2025, 10:24:26 AM
Fundamental Rating

3

RYTM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. RYTM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RYTM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RYTM has reported negative net income.
In the past year RYTM has reported a negative cash flow from operations.
RYTM had negative earnings in each of the past 5 years.
In the past 5 years RYTM always reported negative operating cash flow.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RYTM has a Return On Assets (-50.55%) which is in line with its industry peers.
RYTM's Return On Equity of -141.04% is on the low side compared to the rest of the industry. RYTM is outperformed by 61.57% of its industry peers.
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROIC N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 89.25%, RYTM belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
RYTM's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
RYTM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RYTM has been reduced compared to a year ago.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

RYTM has an Altman-Z score of 11.66. This indicates that RYTM is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 11.66, RYTM belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
RYTM has a Debt/Equity ratio of 0.79. This is a neutral value indicating RYTM is somewhat dependend on debt financing.
RYTM has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: RYTM underperforms 74.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 11.66
ROIC/WACCN/A
WACC10.04%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.79 indicates that RYTM has no problem at all paying its short term obligations.
The Current ratio of RYTM (2.79) is worse than 66.79% of its industry peers.
A Quick Ratio of 2.64 indicates that RYTM has no problem at all paying its short term obligations.
The Quick ratio of RYTM (2.64) is worse than 66.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.64
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.11% over the past year.
RYTM shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.34%.
RYTM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 245.69% yearly.
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%

3.2 Future

RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.60% yearly.
The Revenue is expected to grow by 61.64% on average over the next years. This is a very strong growth
EPS Next Y31.6%
EPS Next 2Y23.43%
EPS Next 3Y29.98%
EPS Next 5Y31.6%
Revenue Next Year46.82%
Revenue Next 2Y53.46%
Revenue Next 3Y62.52%
Revenue Next 5Y61.64%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RYTM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

RYTM's earnings are expected to grow with 29.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.43%
EPS Next 3Y29.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (9/30/2025, 10:24:26 AM)

101.63

+0.99 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners97.8%
Inst Owner Change0.48%
Ins Owners0.67%
Ins Owner Change0.43%
Market Cap6.75B
Analysts87
Price Target114.75 (12.91%)
Short Float %8.25%
Short Ratio8.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.01%
Min EPS beat(2)-13.18%
Max EPS beat(2)-8.85%
EPS beat(4)2
Avg EPS beat(4)-2.55%
Min EPS beat(4)-13.18%
Max EPS beat(4)11.07%
EPS beat(8)4
Avg EPS beat(8)-1.33%
EPS beat(12)7
Avg EPS beat(12)1.68%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)1
Avg Revenue beat(2)-5.75%
Min Revenue beat(2)-20.47%
Max Revenue beat(2)8.98%
Revenue beat(4)3
Avg Revenue beat(4)-1.17%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)3
Avg Revenue beat(8)-2.24%
Revenue beat(12)5
Avg Revenue beat(12)0.92%
Revenue beat(16)8
Avg Revenue beat(16)14.5%
PT rev (1m)1.29%
PT rev (3m)34.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.68%
EPS NY rev (1m)-1.8%
EPS NY rev (3m)-11.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.05%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)6.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.19
P/FCF N/A
P/OCF N/A
P/B 50.53
P/tB 52.8
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)-2.14
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS2.35
BVpS2.01
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.25%
FCFM N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.64
Altman-Z 11.66
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y31.6%
EPS Next 2Y23.43%
EPS Next 3Y29.98%
EPS Next 5Y31.6%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%
Revenue Next Year46.82%
Revenue Next 2Y53.46%
Revenue Next 3Y62.52%
Revenue Next 5Y61.64%
EBIT growth 1Y56.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.21%
EBIT Next 3Y29.52%
EBIT Next 5YN/A
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.04%
OCF growth 3YN/A
OCF growth 5YN/A